BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3488028)

  • 1. [Studies on adoptive immunotherapy using recombinant interleukin 2].
    Sugiyama Y; Takao H; Saji S; Sakata K
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1307-13. PubMed ID: 3488028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of serum immunosuppressive factors on the cytotoxicity of lymphokine-activated killer (LAK) cells induced by recombinant interleukin 2(R-IL2)].
    Takao H; Saji S; Sugiyama Y; Tachibana S; Goshima H; Kunii Y; Sakata K
    Nihon Geka Gakkai Zasshi; 1988 Jul; 89(7):992-8. PubMed ID: 2975748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experimental studies on induction of various lymphokine-activated killer cells using recombinant interleukin 2].
    Takao H; Saji S; Sugiyama Y; Tachibana S; Goshima H; Morita T; Sakata K
    Nihon Geka Gakkai Zasshi; 1988 May; 89(5):646-54. PubMed ID: 3261830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
    Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
    Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
    Melder RJ; Whiteside TL; Vujanovic NL; Hiserodt JC; Herberman RB
    Cancer Res; 1988 Jun; 48(12):3461-9. PubMed ID: 3259468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy.
    Hong WS; Kim CM; Lee JO; Kang TW; Yun TK; Kim CY
    Jpn J Clin Oncol; 1990 Mar; 20(1):87-93. PubMed ID: 2108272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cytotoxicity of interleukin 2-induced lymphocytes and effects of serum immunosuppressive factors].
    Sugiyama Y; Takao H; Umemoto T; Niwa H; Kida H; Saji S; Sakata K
    Nihon Geka Gakkai Zasshi; 1986 Jan; 87(1):3-9. PubMed ID: 3007973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
    Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
    Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
    Lee K; O'Donnell RW; Cockett AT
    J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
    Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL
    J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lymphokine-activated killer (LAK) adoptive immunotherapy: optimal method for large-scale LAK induction].
    Nii A; Sone S; Okubo A; Fawzy F; Yanagawa H; Ogura T
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1871-6. PubMed ID: 3496049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation.
    Gambacorti-Passerini C; Rivoltini L; Radrizzani M; Belli F; Sciorelli G; Ravagnani F; Galazka AR; Cascinelli N; Parmiani G
    Cancer Res; 1989 Sep; 49(18):5230-4. PubMed ID: 2788498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical studies of adoptive immunotherapy of human disseminated brain tumors with LAK cells and recombinant interleukin-2].
    Okamoto Y; Shimizu K; Miyao Y; Yamada M; Ushio Y; Matsui Y; Hayakawa T; Tago H; Ikeda H
    No To Shinkei; 1986 Jun; 38(6):593-8. PubMed ID: 3488068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative study on cytotoxicity of lymphocytes from different tissues in laryngeal cancer].
    An W
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(5):292-4, 314-5. PubMed ID: 8192933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adoptive immunotherapy of cancer patients with lymphokine-activated killer cells].
    Taguchi T; Domoto K
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):914-21. PubMed ID: 3494428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of lymphokine-activated killer activities in peripheral blood lymphocytes and regional lymph node lymphocytes against PC-9 cultured adenocarcinoma and autologous pulmonary adenocarcinoma cells.
    Morikawa Y; Watanabe S; Kodama T
    Jpn J Clin Oncol; 1987 Jun; 17(2):129-39. PubMed ID: 3497285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.